TCA
PTGX icon

Taconic Capital Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Taconic Capital Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$4.37M – 26
2025
Q4 		$4.37M Buy
+50,000
New +$4.09M 1.24% 16

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Taconic Capital Advisors's PTGX Position: Q1 2026 in Review

Taconic Capital Advisors sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 5,000 shares — an estimated $437K sold.

Taconic Capital Advisors first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $437K in Q4 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Taconic Capital Advisors reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Taconic Capital Advisors sold 5,000 Protagonist Therapeutics shares in Q1 2026, an estimated $437K.
  • Taconic Capital Advisors first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
  • Taconic Capital Advisors's Protagonist Therapeutics position peaked at $437K in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Taconic Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.